Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [2]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-86719 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- MRP2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Downregulation of Renal MRPs Transporters in Acute Lymphoblastic Leukemia Mediated by the IL-6/STAT3/PXR Signaling Pathway.
Zhou Y, Nie AQ, Chen S, Wang MM, Yin R, Tang BH, Wu YE, Yang F, Du B, Shi HY, Yang XM, Hao GX, Guo XL, Han QJ, Zheng Y, Zhao W
Journal of inflammation research 2021;14:2239-2252
Journal of inflammation research 2021;14:2239-2252
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of MRP2 in Lane 1: mouse liver tissue (40 µg), Lane 2: rat liver tissue (40 µg), Lane 3: The Spleen tissue lysate of Mouse(40 µg), Lane 4: HepG2 whole cell lysate (40 µg), Lane 5: L02 whole cell lysate (40 µg), Lane 6: HEK293T whole cell lysate (40 µg), Lane 7: A549 whole cell lysate (40 µg). Sample was incubated with MRP2 polyclonal antibody (Product # PA5-86719) using a 1:500 dilution.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of MRP2 in Lane 1: HeLa cell lysate, Lane 2: mouse brain tissue lysate, Lane 3: H9C2 cell lysate. Sample was incubated with MRP2 polyclonal antibody (Product # PA5-86719) using a 1:500 dilution.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Expression of MRPs transporters in HK-2. ( A ) HK-2 cells were exposed to 10 ng/mL IL-6 with STAT3 and PXR siRNA for subsequent Western blotting. ( B - D ) Protein expression of targeted transporters was quantified and is viewed in the bar graphs. * p < 0.05, ** p < 0.01, versus control group. ( E ) The fold change with respect to mRNA expression of STAT3, PXR, MRP2 , and MRP4 in HK-2 cells treated with IL-6 (10 ng/mL) compared to HK-2 cells. ** p < 0.01, versus control group.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Expression of targeted renal proteins and mRNA in NOD/SCID mice treated with Tocilizumab. ( A ) Expression of target proteins in NOD/SCID mice detected using Western blotting. ( B ) Expression of targeted proteins was quantified and can be seen in the bar graphs. *p < 0.05, ** p < 0.01, versus the control group; # p < 0.05, ## p < 0.01, the ALL-TCZ group versus the ALL group. ( C ) The fold change with respect to mRNA expression of Stat3, Pxr, Mrp2 , and Mrp4 in NOD/SCID mice. * p < 0.05, ** p < 0.01, versus the control group.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Expression of targeted renal proteins and mRNA in NOD/SCID mice treated with S3I-201. ( A ) Expression of target proteins in NOD/SCID mice kidney detected using Western blotting. ( B ) Expression of targeted proteins was quantified and can be seen in the bar graphs. *p < 0.05, ** p < 0.01, versus the control group; # p < 0.05, ## p < 0.01, the ALL-S3I-201 group versus the control group. ( C ) The fold change with respect to mRNA expression of Stat3, Pxr, Mrp2 , and Mrp4 in NOD/SCID mice. * p < 0.05, ** p < 0.01, versus the control group.
